Same day, different holiday: Mid-autumn festivals across East Asia
Yoon hosts luncheon meeting with Korean atomic bomb victims in Hiroshima on Chuseok
Swimmer, gamers celebrate Chuseok with gold medals
With teammate's help, inconsolable shooter regroups in time to win bronze
The many regional flavors of songpyeon, a Korean holiday dessert
NewJeans hits 1 bln streams mark on Spotify with debut album
Traffic heavy on expressways following Chuseok
Diplomatic vehicle blessed for safety via Hindu ritual by S. Korean Embassy in India
Expressway traffic congestion persists on 2nd day of extended Chuseok holiday
Post-pandemic Chuseok to revive overseas travel, gift giving
Celltrion's new Humira biosimilar wins approval in CanadaBy Yonhap
Published : Dec. 30, 2021 - 14:53
Yuflyma, an adalimumab biosimilar with a high concentration, is used to treat patients with rheumatoid arthritis, psoriasis and inflammatory diseases.
Yuflyma requires only half the solution administered to patients compared with the existing Humira biosimilar and is also citrate-free, which lessens discomfort during injection.
Celltrion received authorization for Yuflyma in Europe in February and is preparing to roll out the biosimilar in South Korea after getting approval in October.
Humira was the second most-sold biologic drug in Canada last year with total sales reaching 1 trillion won ($842.5 billion). Celltrion said it plans to actively target the Canadian market with the authorization of Yuflyma. (Yonhap)
S. Korea wins bronze in pistol mixed team event for 14th shooting medal
Heavy traffic on expressways expected on 4th day of holiday
Police launch belated probe into another teacher's suicide after parental harassment